141 related articles for article (PubMed ID: 25511681)
1. Novel therapeutic combination demonstrates more than additive effects in cutaneous T-cell lymphoma.
Dulmage BO; Story SK; Falo LD; Geskin LJ
Leuk Lymphoma; 2015 Jul; 56(7):2225-7. PubMed ID: 25511681
[No Abstract] [Full Text] [Related]
2. Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma.
Cortes JR; Patrone CC; Quinn SA; Gu Y; Sanchez-Martin M; Mackey A; Cooke AJ; Shih BB; Laurent AP; Trager MH; Ferrando AA; Geskin LJ; Palomero T
J Invest Dermatol; 2021 Dec; 141(12):2908-2920.e7. PubMed ID: 34089720
[TBL] [Abstract][Full Text] [Related]
3. Romidepsin and interferon gamma: a novel combination for refractory cutaneous T-cell lymphoma.
Samimi S; Morrissey K; Anshelevich S; Evans K; Gardner J; Musiek A; Vittorio C; Rook A; Kim E
J Am Acad Dermatol; 2013 Jan; 68(1):e5-6. PubMed ID: 23244387
[No Abstract] [Full Text] [Related]
4. [Cutaneous lymphoma].
Beyeler M; Burg G; Dummer R
Hautarzt; 2004 Oct; 55(10):1005-16; quiz 1017. PubMed ID: 15349694
[TBL] [Abstract][Full Text] [Related]
5. Nodal peripheral T-cell lymphoma with secondary granulomatous cutaneous involvement.
Marzano AV; Vanotti M; Boneschi V; Gianelli U; Alessi E
Acta Derm Venereol; 2004; 84(4):325-7. PubMed ID: 15339087
[No Abstract] [Full Text] [Related]
6. Treatment of cutaneous T-cell lymphoma by retinoids and calcitriol.
Bagot M
Lancet; 1995 Aug; 346(8971):376-7. PubMed ID: 7623547
[No Abstract] [Full Text] [Related]
7. Evaluation of a 1-h exposure time to mechlorethamine in patients undergoing topical treatment.
Foulc P; Evrard V; Dalac S; Guillot B; Delaunay M; Verret JL; Dréno B
Br J Dermatol; 2002 Nov; 147(5):926-30. PubMed ID: 12410702
[TBL] [Abstract][Full Text] [Related]
8. In brief: mechlorethamine gel (Valchlor) for cutaneous T-Cell lymphoma.
Med Lett Drugs Ther; 2015 Apr; 57(1467):e66. PubMed ID: 25988964
[No Abstract] [Full Text] [Related]
9. Cutaneous T cell lymphoma of the hand.
Medvedofsky D; Mekori YA; Mor A
Isr Med Assoc J; 2008 Nov; 10(11):827-8. PubMed ID: 19070298
[No Abstract] [Full Text] [Related]
10. Angioimmunoblastic T-cell lymphoma with cutaneous involvement.
Mahendran R; Grant JW; Hoggarth CE; Burrows NP
J Eur Acad Dermatol Venereol; 2001 Nov; 15(6):589-90. PubMed ID: 11843225
[No Abstract] [Full Text] [Related]
11. T-zone lymphoma with cutaneous involvement: a case report and review of the literature.
Kazakov DV; Kempf W; Michaelis S; Schmid U; Cogliatti S; Dummer R; Burg G
Br J Dermatol; 2002 Jun; 146(6):1096-100. PubMed ID: 12072087
[TBL] [Abstract][Full Text] [Related]
12. A case of primary cutaneous CD4+ small- to medium-sized pleomorphic T-cell lymphoma.
Hou S; Liu X; Liu J; Zhang Z; Wang B; Han C
Eur J Dermatol; 2016 Dec; 26(6):629-630. PubMed ID: 27629423
[No Abstract] [Full Text] [Related]
13. CD4/CD8 double-negative T-cell lymphoma: a variant of primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma?
Miyauchi T; Abe R; Morita Y; Adachi M; Shiba K; Hamade Y; Saito N; Nishimura M; Ibata M; Okada K; Shigematsu A; Endo T; Kawai K; Teshima T; Shimizu H
Acta Derm Venereol; 2015 Nov; 95(8):1024-5. PubMed ID: 25792011
[No Abstract] [Full Text] [Related]
14. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
Kato Y; Egusa C; Maeda T; Tsuboi R
J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
[TBL] [Abstract][Full Text] [Related]
15. Primary cutaneous blastic natural killer-cell lymphoma.
Conde-Taboada A; De La Torre C; Alcázar JJ; Dios A; Flórez A; Rosón E; Cruces M
Acta Derm Venereol; 2006; 86(3):269-70. PubMed ID: 16710598
[No Abstract] [Full Text] [Related]
16. Epigenetic Regulation of Apoptosis in Cutaneous T-Cell Lymphoma: Implications for Therapy with Methotrexate, Jak Inhibitors, and Resveratrol.
Nihal M; Wu J; Stonesifer CJ; Daniels J; Choi J; Geskin L; Rook AH; Wood GS
J Invest Dermatol; 2022 Feb; 142(2):493-496.e7. PubMed ID: 34358529
[No Abstract] [Full Text] [Related]
17. Cutaneous T-cell lymphoma presenting with diffuse lymphomatous infiltration of the peripheral nerves: response to combination chemotherapy.
Atiq OT; DeAngelis LM; Rosenblum M; Portlock CS
Am J Clin Oncol; 1992 Jun; 15(3):212-5. PubMed ID: 1375431
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of Brentuximab Vedotin in advanced cutaneous T-Cell lymphomas patients.
Papadavid E; Kapniari E; Marinos L; Nikolaou V; Oikonomidi A; Georgakopoulos J; Stratigos A; Kouloulias V; Pappa V
J Eur Acad Dermatol Venereol; 2019 May; 33(5):e223-e225. PubMed ID: 30821007
[No Abstract] [Full Text] [Related]
19. Leukaemic presentation of angioimmunoblastic T-cell lymphoma.
Lin KW; Lee YS; Phipps C
Br J Haematol; 2014 Sep; 166(6):808. PubMed ID: 24974735
[No Abstract] [Full Text] [Related]
20. Extracorporeal photochemotherapy in the early treatment of cutaneous T-cell lymphoma.
Fimiani M; Rubegni P; D'Ascenzo G; Andreassi L
J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):828-30. PubMed ID: 7929941
[No Abstract] [Full Text] [Related]
[Next] [New Search]
